One of the most striking findings of the VapeScan Study was that vaping alone or vaping plus smoking provided no risk reduction for hypertension compared to never vaping or smoking. This challenges the narrative that vaping is a safer alternative to smoking for cardiovascular health.
What the data shows: The vaping/never smoking group had the highest blood pressure, not the lowest. Dual users (vaping plus smoking) did not show significantly higher blood pressure than the control group, but this does not mean dual use is safe — it means the study may not have had enough statistical power to detect the combined effect. The key takeaway is that vaping does not reduce cardiovascular risk compared to not using any tobacco or nicotine products.
This finding is particularly important for young adults who started vaping without ever smoking. The harm reduction argument for vaping typically applies to adult smokers who switch to e-cigarettes to reduce exposure to combustion byproducts. But the VapeScan Study shows that for never-smokers, vaping introduces cardiovascular risk that would not otherwise exist.
For context on the switching debate, our [menthol vape switching science analysis](menthol-vape-switching-science-full) covers the evidence on switching rates from smoking to vaping. The VapeScan findings do not contradict the switching evidence — they simply highlight that vaping is not risk-free, especially for never-smokers.
